Telomerase modRNA Offers a Novel RNA-Based Approach to Treat Human Pulmonary Fibrosis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study explores RNA-based telomerase (hTERT) therapy for pulmonary fibrosis (PF). Modified RNA (modRNA) hTERT treatment improved lung cell function and reduced fibrosis markers, showing promise for treating this life-threatening lung disease.
Area Of Science
- Biochemistry
- Molecular Biology
- Pulmonary Medicine
Background
- Pulmonary fibrosis (PF) is a progressive lung scarring disease with limited treatment options.
- Current therapies only slow fibrosis progression, with a poor median life expectancy post-diagnosis.
- Telomere attrition is common in PF patients, suggesting telomerase as a therapeutic target.
Purpose Of The Study
- To investigate the therapeutic potential of modified RNA (modRNA) encoding human telomerase reverse transcriptase (hTERT) for pulmonary fibrosis.
- To assess the effects of modRNA hTERT on lung cell proliferation, DNA damage, and telomere length.
- To evaluate the efficacy of modRNA hTERT in preclinical models of human lung fibrosis.
Main Methods
- In vitro transcription of modified nucleoside RNA (modRNA) encoding hTERT.
- Treatment of human lung cells (MRC-5, primary alveolar type II pneumocytes) and 3D precision-cut lung slices with modRNA hTERT.
- Assessment of telomerase activity, cell proliferation, DNA damage, telomere length, senescence markers, and inflammatory/fibrosis mediators (IL6, IL8, TGFβ, COL1A1).
Main Results
- modRNA hTERT transiently activated telomerase in lung cells, increasing proliferation and telomere length while reducing DNA damage.
- Transient immune response observed at high concentrations, returning to baseline within 48 hours.
- Therapeutic proof of concept in ex vivo PF lung slices: single modRNA hTERT treatment reduced senescence, pro-inflammatory markers, and key fibrosis mediators.
Conclusions
- RNA-based hTERT therapy, using modRNA or circular RNA, demonstrates potential for treating human lung fibrosis.
- modRNA hTERT effectively targets key pathological mechanisms in PF, including senescence and fibrosis.
- Further development of RNA-based hTERT strategies is warranted for PF therapeutic applications.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded...
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...